Evidence map›Paper›PMID 36364115›Full record

ArticleMolecules (Basel, Switzerland)2022

Preparation of Paclitaxel-Encapsulated Bio-Functionalized Selenium Nanoparticles and Evaluation of Their Efficacy against Cervical Cancer.

Soumya Menon, Santhoshkumar Jayakodi, Kanti Kusum Yadav, Prathap Somu, Mona Isaq, Venkat Kumar Shanmugam, Amballa Chaitanyakumar, Nagaraj Basavegowda

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026
    Review
  2. Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Soumya MenonDepartment of Chemistry, Indian Institute of Technology, Roorkee 247667, India.
Santhoshkumar JayakodiDepartment of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai 602105, India.ORCID 0000-0002-6784-8431
Kanti Kusum YadavDepartment of Biotechnology, Karunya Institute of Technology and Sciences (Deemed to be University), Karunya Nagar, Coimbatore 641114, India.
Prathap SomuDepartment of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai 602105, India.ORCID 0000-0002-3615-8200
Mona IsaqDepartment of Biotechnology & Bioinformatics, Kuvempu University, Jnana Sahyadri, Shankaraghatta, Shivamogga 577451, India.
Venkat Kumar ShanmugamSchool of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore 632014, India.
Amballa ChaitanyakumarDepartment of Biotechnology, University Institute of Engineering and Technology, Guru Nanak University, Hyderabad 500085, India.
Nagaraj BasavegowdaDepartment of Biotechnology, Yeungnam University, Gyeongsan 712-749, Korea.
Saveetha University · INGuru Nanak Institutions · INIndian Institute of Technology Roorkee · INKarunya University · INKuvempu University · INVellore Institute of Technology University · INYeungnam University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potentiality of nanomedicine in the cancer treatment being widely recognized in the recent years. In the present investigation, the synergistic effects of chitosan-modified selenium nanoparticles loaded with paclitaxel (PTX-chit-SeNPs) were studied. These selenium nanoparticles were tested for drug release analysis at a pH of 7.4 and 5.5, and further characterized using FTIR, DLS, zeta potential, and TEM to confirm their morphology, and the encapsulation of the drug was carried out using UPLC analysis. Quantitative evaluation of anti-cancer properties was performed via MTT analysis, apoptosis, gene expression analysis, cell cycle arrest, and over-production of ROS. The unique combination of phytochemicals from the seed extract, chitosan, paclitaxel, and selenium nanoparticles can be effectively utilized to combat cancerous cells. The production of the nanosystem has been demonstrated to be cost-effective and have unique characteristics, and can be utilized for improving future diagnostic approaches.

Indexed as

ChitosanNanoparticlesSeleniumUterine Cervical NeoplasmsCell Line, TumorFemaleHumansPaclitaxelChitosanPaclitaxelSeleniumanticancercervical cancerchitosanflow cytometerMucuna pruriens seed extractpaclitaxelselenium nanoparticles

Identifiers

PMID36364115
PMCPMC9655580
OpenAlexW4307358454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.